ERBB2 and neoplasm: For HER2-20 insertion mutations, poziotinib and pyrotinib have been shown their efficacy, and the latest ADC drug, trastuzumab deruxtecan (T-DXd), has brought unprecedented tumor remission rate and control time (12).